Studies on hydralazine. III. Bioavailability of hydralazine in man
- PMID: 1001354
- DOI: 10.1007/BF00563075
Studies on hydralazine. III. Bioavailability of hydralazine in man
Abstract
The bioavailability of orally administered hydralazine was assessed in 4 healthy subjects after separate administration of a single oral or intravenous dose (0.3 mg-kg-1). Comparison of the areas under the serum concentration-time curves showed that 26-55% of the oral dose was available to the systemic circulation as unchanged drug. The 0-24 h excretion of the drug in urine was rapid: 11.4-14.1% of the dose after intravenous administration, and 2.0-3.6% after an oral dose. Acetylation of hydralazine leads to formation of 3-methyl-s-triazolo-3,4, aphthalazine (MTP) and a gas-liquid-chromatographic method for its measurement in urine was developed. After oral and intravenous administration, 0.8-1.2% and 1.4-2.3% of the dose, respectively, were recovered within 24 hours from urine as MTP. After oral administration there was a relative increase in the amount of MTP in every subject, which indicates route-dependent metabolism. The lower bioavailability of oral hydralazine could be explained in terms of first-pass metabolism.
Similar articles
-
Kinetics of hydralazine elimination.Clin Pharmacol Ther. 1977 Jun;21(6):715-20. doi: 10.1002/cpt1977216715. Clin Pharmacol Ther. 1977. PMID: 862310
-
Polymorphic acetylation of hydralazine.Clin Pharmacol Ther. 1980 Sep;28(3):350-5. doi: 10.1038/clpt.1980.173. Clin Pharmacol Ther. 1980. PMID: 7408395
-
Determinants of systemic availability of oral hydralazine in heart failure.Clin Pharmacol Ther. 1985 Nov;38(5):538-43. doi: 10.1038/clpt.1985.220. Clin Pharmacol Ther. 1985. PMID: 4053489
-
First-pass elimination. Basic concepts and clinical consequences.Clin Pharmacokinet. 1984 Jan-Feb;9(1):1-25. doi: 10.2165/00003088-198409010-00001. Clin Pharmacokinet. 1984. PMID: 6362950 Review.
-
Hydralazine therapy for hypertension during the anesthetic and postanesthetic periods.Int Anesthesiol Clin. 1978 Summer;16(2):299-312. doi: 10.1097/00004311-197816020-00013. Int Anesthesiol Clin. 1978. PMID: 357299 Review. No abstract available.
Cited by
-
Drug kinetics and hepatic blood flow.Clin Pharmacokinet. 1979 Nov-Dec;4(6):433-48. doi: 10.2165/00003088-197904060-00003. Clin Pharmacokinet. 1979. PMID: 391463 Review. No abstract available.
-
Pharmacokinetics of hydralazine and its acid-labile hydrazone metabolites in relation to acetylator phenotype.J Pharmacokinet Biopharm. 1980 Feb;8(1):53-68. doi: 10.1007/BF01059448. J Pharmacokinet Biopharm. 1980. PMID: 7381691
-
Drug metabolism by the gastrointestinal mucosa.Clin Pharmacokinet. 1981 Jul-Aug;6(4):259-74. doi: 10.2165/00003088-198106040-00002. Clin Pharmacokinet. 1981. PMID: 6113909
-
Pharmacokinetics of bendroflumethiazide alone and in combination with propranolol and hydralazine.Eur J Clin Pharmacol. 1982;21(4):315-23. doi: 10.1007/BF00637620. Eur J Clin Pharmacol. 1982. PMID: 7056277
-
The Segregated Intestinal Flow Model (SFM) for Drug Absorption and Drug Metabolism: Implications on Intestinal and Liver Metabolism and Drug-Drug Interactions.Pharmaceutics. 2020 Apr 1;12(4):312. doi: 10.3390/pharmaceutics12040312. Pharmaceutics. 2020. PMID: 32244748 Free PMC article. Review.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources